Resources, Workforce Development, and Animal Models for the Rutgers RBL
Project Number5UC7AI180307-02
Contact PI/Project LeaderALLAND, DAVID
Awardee OrganizationRUTGERS BIOMEDICAL AND HEALTH SCIENCES
Description
Abstract Text
Overall ABSTRACT
The Rutgers University Regional Biocontainment Laboratory (RBL) serves as a central facility to perform
biosafety level three (BSL3) therapeutic, pathogenesis, and diagnostic research on high threat biological agents
with a focus on Mycobacterium tuberculosis and SARS-CoV-2, as well as other category A, B, and C pathogens.
The RBL serves academic and commercial entities within Rutgers University, the Northeast United States and
nationally, while also engaging globally with companies and academic institutions through collaborations and
research contracts. This proposal will provide support that enhances the RBL’s ability to fulfill its research and
biothreat response/pandemic preparedness missions while also supporting an expanding faculty/staff. We
propose to accomplish these goals by improving the RBL facilities, support services, BSL3 practice development
and implementation and special services offerings though the execution of three aims: Aim 1. Establish a Facility
management, maintenance and operations (FMMO) core. Aim 2. Establish a BSL-3 Practices core (Practice
core). Aim 3. Establish a biocontainment research support service core devoted to developing animal models of
BSL3 pathogens and associated support services (Animal models and related services, or AMRS core). The
FMMO core will provide BSL3 and ABSL3 services, management and oversight, for routine animal husbandry,
microbiology and virology services in support of investigators grant funded research projects while ensuring
efficient operations and maintenance of the BSL3 facilities and providing trained staff to support the BSL3
building systems and equipment. The Practice core will develop and maintain standard operating procedures
and training for research in the RBL BSL3 laboratories including best practices, emergency response, waste
management, shipping, husbandry, select agent-specific practices and inventory. It will also develop and conduct
biosecurity and disaster drills and liaise with other BSL3 laboratories within the RBL network as well as local,
state and federal health agencies to coordinate operations and plan for joint responses to new infectious disease
threats. The AMRS core will develop critical animal models including those of SARS-CoV2 and highly pathogenic
influenza virus transmission, COVID-19 PASC, pulmonary impairment after TB (PIAT), and drug treatment
models, and then support grant funded investigators in the performance of these models along with the advanced
instrumentation needed to analyze these infected models and their tissues/cells in a BSL3 environment.
Together, these three cores will significantly enhance the near- and long-term abilities of the RBL to address
critical biothreats and emerging infectious diseases requiring study in a BSL3 laboratory setting, while also
increasing our capacity to respond to the next public health emergency or pandemic.
Public Health Relevance Statement
Overall - PROJECT NARRATIVE
This proposal will enhance the capabilities of the Rutgers Regional Biocontainment Laboratory to respond to the
next public health emergency or pandemic by supporting efficient operations and maintenance of its high-level
biosafety laboratory facilities, training and maintaining critical faculty and staff, developing and disseminating
state-of-the art safety and disaster response procedures, and developing scientific models of disease.
NIH Spending Category
No NIH Spending Category available.
Project Terms
2019-nCoVAddressAftercareAnimal HusbandryAnimal ModelAnimalsBacillus anthracisBiological ProductsBudgetsCOVID-19Candida aurisCategoriesCellsCertificationChikungunya virusCollaborationsComputers and Advanced InstrumentationContainmentCryptococcusDevelopmentDiagnosticDiagnostics ResearchDisastersEmergency responseEmerging Communicable DiseasesEnsureEnvironmentEquipmentEquipment and supply inventoriesFacultyFrancisella tularensisFundingGoalsGrantHIVHealthImpairmentInfectious disease threatInstitutionJointsLaboratoriesLaboratory ResearchLife Cycle StagesLungMaintenanceMicrobiologyMissionModelingMonkeypoxMycobacterium tuberculosisPathogenesisPathogenicityPerformancePharmacotherapyPost-Acute Sequelae of SARS-CoV-2 InfectionProceduresResearchResearch ActivityResearch ContractsResearch PersonnelResearch Project GrantsResearch SupportResearch TrainingResourcesSafetyScientistServicesShippingSystemTherapeuticTissuesTrainingTuberculosisUnited StatesUnited States National Institutes of HealthUniversitiesViralVirulentWaste ManagementWorkWorkforce DevelopmentYersinia pestisbiocontainment facilitybiosecuritybiothreatcostdisease modelend of lifeimprovedinfluenzaviruslaboratory facilityoperationpandemic diseasepandemic preparednesspathogenpublic health emergencyrecruitresponsetuberculosis drugstuberculosis treatmentviral transmissionvirology
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
090299830
UEI
YVVTQD8CJC79
Project Start Date
18-August-2023
Project End Date
31-July-2028
Budget Start Date
01-August-2024
Budget End Date
31-July-2025
Project Funding Information for 2024
Total Funding
$4,189,403
Direct Costs
$2,905,603
Indirect Costs
$1,283,800
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$4,189,403
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5UC7AI180307-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5UC7AI180307-02
Patents
No Patents information available for 5UC7AI180307-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5UC7AI180307-02
Clinical Studies
No Clinical Studies information available for 5UC7AI180307-02
News and More
Related News Releases
No news release information available for 5UC7AI180307-02
History
No Historical information available for 5UC7AI180307-02
Similar Projects
No Similar Projects information available for 5UC7AI180307-02